United Therapeutics Valuation
Is UTHR * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of UTHR * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: UTHR * (MX$6902.22) is trading below our estimate of fair value (MX$14569.74)
Significantly Below Fair Value: UTHR * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for UTHR *?
Key metric: As UTHR * is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is UTHR *'s PE Ratio? | |
|---|---|
| PE Ratio | 15x |
| Earnings | US$1.11b |
| Market Cap | US$16.65b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.5x |
| Enterprise Value/EBITDA | 8.8x |
| PEG Ratio | 1.9x |
Price to Earnings Ratio vs Peers
How does UTHR *'s PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 70.5x | ||
BMRN BioMarin Pharmaceutical | 38x | 27.3% | US$12.2b |
NBIX Neurocrine Biosciences | 33x | 29.6% | US$12.7b |
GMAB Genmab | 20x | 23.7% | DKK 94.2b |
A068270 Celltrion | 191.2x | 73.6% | ₩35.8t |
UTHR * United Therapeutics | 15x | 8.1% | Mex$16.6b |
Price-To-Earnings vs Peers: UTHR * is good value based on its Price-To-Earnings Ratio (15x) compared to the peer average (70.5x).
Price to Earnings Ratio vs Industry
How does UTHR *'s PE Ratio compare vs other companies in the Global Biotechs Industry?
| 18 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 18 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: UTHR * is good value based on its Price-To-Earnings Ratio (15x) compared to the Global Biotechs industry average (25.5x).
Price to Earnings Ratio vs Fair Ratio
What is UTHR *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 15x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate UTHR *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
ICON
US$17.7b
A clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally.
ICLR N
US$4,286.08
7D
0%
1Y
-7.7%
CSPC Pharmaceutical Group
HK$69.4b
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally.
1093 N
HK$15.69
7D
0%
1Y
-27.0%
Exact Sciences
US$13.1b
Provides cancer screening and diagnostic test products in the United States and internationally.
EXAS *
US$872.00
7D
0%
1Y
n/a